Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia

• Published in: Progress in neuro-psychopharmacology & biological psychiatry 2011-01, Vol.35 (1), p.78-83
• Main Authors: Ogino, Shin, Miyamoto, Seiya, Tenjin, Tomomi, Kitajima, Rei, Ojima, Kazuaki, Miyake, Nobumi, Funamoto, Yasuyuki, Arai, Jun, Tsukahara, Sachiko, Ito, Yukie, Tadokoro, Masanori, Anai, Kiriko, Tatsunami, Shinobu, Kubota, Hiroshi, Kaneda, Yasuhiro, Yamaguchi, Noboru
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adult and adolescent clinical studies; Analysis of Variance; Biological and medical sciences; Biperiden; Biperiden - therapeutic use; Cognition Disorders - drug therapy; Cognition Disorders - etiology; Cognitive function; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Male; Medical sciences; Middle Aged; Muscarinic Antagonists - therapeutic use; Neuropharmacology; Neuropsychological Tests; Pharmacology. Drug treatments; Psychiatric Status Rating Scales; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Quality of life; Retrospective Studies; Schizophrenia; Schizophrenia - complications; Schizophrenia - drug therapy; Second-generation antipsychotics; Young Adult
• ISSN: 0278-5846; 1878-4216
• DOI: 10.1016/j.pnpbp.2010.08.030

The high use of long-term antiparkinsonian anticholinergic drugs with antipsychotics has been identified as an important issue in the treatment of schizophrenia in Japan. The aim of this study was to evaluate the effects of gradual discontinuation of biperiden, an anticholinergic drug, on cognitive function and quality of life (QOL) in schizophrenia. Thirty-four schizophrenic patients who had received a second-generation antipsychotic (SGA) with concomitant biperiden for at least 3months were enrolled. Before and 4weeks after discontinuation of biperiden, the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) and the Schizophrenia Quality of Life Scale (SQLS-J) were administered. Clinical evaluation also included the Positive and Negative Syndrome Scale (PANSS). To compare the practice effect on BACS-J, 10 chronic patients with schizophrenia were assessed without tapering biperiden. Biperiden was discontinued safely in most patients, and no emergent extrapyramidal symptoms were observed. Significant improvements were shown in attention, processing speed, and composite score, as measured by the BACS-J without practice effect. In addition, the psychosocial condition score on the SQLS-J and the general psychopathology score on the PANSS significantly improved after biperiden discontinuation. Discontinuation of long-term biperiden use may be warranted in patients with schizophrenia treated with SGAs, as it may improve cognitive function, subjective QOL, and psychiatric symptoms with no significant adverse effects. ► The chronic use of biperiden may decrease cognitive function in schizophrenia. ► Biperiden can be discontinued by gradual dose reduction without adverse effects. ► Biperiden reduction at a rate of 1 mg/2-4weeks is a safe discontinuation strategy. ► Discontinuing biperiden use can improve attention and processing speed. ► Discontinuing biperiden use can improve subjective QOL and psychiatric symptoms.